Fusarium graminearum is a notorious pathogen that causes Fusarium head blight (FHB) in cereal crops. It produces secondary metabolites, such as deoxynivalenol, diminishing grain quality and leading to lesser crop yield. Many strategies have been developed to combat this pathogenic fungus; however, considering the lack of resistant cultivars and likelihood of environmental hazards upon using chemical pesticides, efforts have shifted toward the biocontrol of plant diseases, which is a sustainable and eco-friendly approach. Fengycin, derived from Bacillus amyloliquefaciens FZB42, was purified from the crude extract by HPLC and further analyzed by MALDI-TOF-MS. Its application resulted in structural deformations in fungal hyphae, as observed via scanning electron microscopy. In planta experiment revealed the ability of fengycin to suppress F. graminearum growth and highlighted its capacity to combat disease incidence. Fengycin significantly suppressed F. graminearum, and also reduced the deoxynivalenol (DON), 3-acetyldeoxynivalenol (3-ADON), 15-acetyldeoxynivalenol (15-ADON), and zearalenone (ZEN) production in infected grains. To conclude, we report that fengycin produced by B. amyloliquefaciens FZB42 has potential as a biocontrol agent against F. graminearum and can also inhibit the mycotoxins produced by this fungus.

Diabetic DNI differs from non-diabetic DNI in several aspects and is associated with a higher morbidity. A greater than normal haemoglobin A1c level was commonly observed.

Two experiments were conducted to examine the effect of zinc (Zn) source on the performance, Zn status, immune response, and rumen fermentation of lactating cows to find the most available Zn source for dairy production. In Experiment 1, a total of 30 multiparous Holstein cows were randomly allocated by body weight and milk yield to one of five treatments in a completely randomized design. Cows were fed a total mixed ration (TMR) with no Zn addition (containing 37.60 mg Zn/kg TMR by analysis), and the basal TMR supplemented with 40 mg Zn/kg TMR from either Zn sulfate or one of three organic Zn chelates with weak (Zn-AA W), moderate (Zn-Pro M), or strong (Zn-Pro S) chelation strengths, respectively for 55 days. In Experiment 2, the in vitro rumen fermentation method was used in a completely randomized design involving a 4 × 3 factorial arrangement of treatments. The four Zn sources were the same as those used in Experiment 1, and the three supplemental Zn levels in the rumen fluid were 0, 10, and 20 μg/mL, respectively. The feed intake, milk composition, and somatic cell count (SCC) were unaffected (P > 0.05) by treatments. However, the milk yield was increased (P < 0.05) by addition of Zn from both the Zn-AA W and Zn-Pro S. Plasma Zn level at the end of the experiment was increased (P < 0.05) by addition of Zn from all three organic sources. Serum antibody titers on day 21 after vaccination with foot and mouth disease (FMD) vaccine were increased (P < 0.05) by both supplemental Zn-AA W and Zn-Pro S. The organic Zn sources with different chelation strengths supplemented at the added Zn level of 10 μg/mL were more effective (P < 0.05) in improving the rumen fermentation than Zn sulfate, with the most effective being Zn-AA W. In conclusion, Zn source had no influence on the feed intake, milk composition, and SCC; however, both the Zn-AA W and Zn-Pro S were more effective than Zn-Pro M and Zn sulfate in enhancing the rumen fermentation, Zn status, and humoral immune response as well as improving milk yield of lactating cows. The improved milk production might be attributed to the improved rumen fermentation, Zn status, and immune function.

Background Hepatocellular carcinoma (HCC) with high heterogeneity is one of the most frequent malignant tumors throughout the world. However, there is no research to establish a ferroptosis-related lncRNAs (FRlncRNAs) signature for the patients with HCC. Therefore, this study was designed to establish a novel FRlncRNAs signature to predict the survival of patients with HCC. Method The expression profiles of lncRNAs were acquired from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database. FRlncRNAs co-expressed with ferroptosis-related genes were utilized to establish a signature. Cox regression was used to construct a novel three FRlncRNAs signature in the TCGA cohort, which was verified in the GEO validation cohort. Results Three differently expressed FRlncRNAs significantly associated with prognosis of HCC were identified, which composed a novel FRlncRNAs signature. According to the FRlncRNAs signature, the patients with HCC could be divided into low- and high-risk groups. Patients with HCC in the high-risk group displayed shorter overall survival (OS) contrasted with those in the low-risk group (P < 0.001 in TCGA cohort and P = 0.045 in GEO cohort). This signature could serve as a significantly independent predictor in Cox regression (multivariate HR > 1, P < 0.001), which was verified to a certain extent in the GEO cohort (univariate HR > 1, P < 0.05). Meanwhile, it was also a useful tool in predicting survival among each stratum of gender, age, grade, stage, and etiology,etc. This signature was connected with immune cell infiltration (i.e., Macrophage, Myeloid dendritic cell, and Neutrophil cell, etc.) and immune checkpoint blockade targets (PD-1, CTLA-4, and TIM-3). Conclusion The three FRlncRNAs might be potential therapeutic targets for patients, and their signature could be utilized for prognostic prediction in HCC.